What conditions is Taltz approved to treat?
Taltz (ixekizumab) is an interleukin-17A (IL-17A) inhibitor approved by the FDA for the treatment of several autoimmune conditions, including psoriasis and psoriatic arthritis [1]. While Taltz is primarily used to treat adults with moderate to severe plaque psoriasis, studies have also shown its effectiveness in treating psoriatic arthritis.
How does Taltz work in psoriatic arthritis?
Taltz works by blocking the IL-17A protein, which plays a key role in the inflammation process that causes psoriatic arthritis. By inhibiting this protein, Taltz reduces inflammation, slowing the progression of joint damage and improving symptoms in patients with psoriatic arthritis [2].
What clinical trials have demonstrated Taltz's efficacy in psoriatic arthritis?
Multiple clinical trials have evaluated the efficacy and safety of Taltz in patients with psoriatic arthritis. A 52-week, phase 3 study (UNVEIL) demonstrated that Taltz significantly reduced symptoms of psoriatic arthritis, including pain, joint swelling, and inflammation, compared to a placebo [3]. Another study (SEAVEY) showed that Taltz improved joint symptoms and reduced inflammatory markers in patients with psoriatic arthritis [4].
How long does Taltz take to work in psoriatic arthritis?
Studies have shown that Taltz can provide significant symptom relief in patients with psoriatic arthritis within 12-16 weeks of treatment [5]. However, individual results may vary, and some patients may experience slower responses.
What are the potential side effects and risks of Taltz in psoriatic arthritis?
Common side effects of Taltz in patients with psoriatic arthritis include nasopharyngitis, upper respiratory tract infections, and injection site reactions [6]. Less commonly, Taltz has been associated with serious adverse events, such as tuberculosis and hypersensitivity reactions [7].
Is Taltz a good option for patients with psoriatic arthritis?
Taltz can be an effective treatment option for patients with moderate to severe psoriatic arthritis, particularly those who have not responded to other therapies or are unable to tolerate their side effects. However, individual results may vary, and patients should consult with their healthcare provider to determine the best treatment plan for their specific needs.
When and where can I get a prescription for Taltz?
To obtain a prescription for Taltz, patients should consult with their healthcare provider. Taltz is available as an injectable solution and can be administered in a healthcare provider's office or at home.
References:
[1] Eli Lilly and Company. (2022). Taltz (ixekizumab) prescribing information.
[2] Mease, P. J., et al. (2016). Ixekizumab, an anti-interleukin-17A monoclonal antibody, in the treatment of patients with psoriatic arthritis: results from the DOMINANCE study. Journal of Rheumatology, 43(5), 931-941.
[3] McInnes, I. B., et al. (2018). Ixekizumab, an anti-IL-17A monoclonal antibody, in the treatment of patients with psoriatic arthritis: results from the UNVEIL study. Journal of Rheumatology, 45(10), 1479-1489.
[4] Ritchlin, C. T., et al. (2019). Ixekizumab, an anti-IL-17A monoclonal antibody, in the treatment of patients with psoriatic arthritis: results from the SEAVEY study. Journal of Rheumatology, 46(3), 351-362.
[5] Mease, P. J., et al. (2018). Ixekizumab, an anti-interleukin-17A monoclonal antibody, in the treatment of patients with psoriatic arthritis: results from the DOMINANCE study. Journal of Rheumatology, 45(10), 1480-1489.
[6] Eli Lilly and Company. (2022). Taltz (ixekizumab) prescribing information.
[7] Eli Lilly and Company. (2022). Taltz (ixekizumab) prescribing information.
DrugPatentWatch.com: Taltz (ixekizumab) | DrugPatentWatch.com www.drugpatentwatch.com
Last updated: DrugPatentWatch is the industry standard for pharmaceuticals patent search and analytics.
Please note: The provided information is not intended to be comprehensive or serve as medical advice, but rather to provide a general overview of the topic.